NEW YORK – Singaporean molecular diagnostics company MirXes believes the results of a new clinical validation study will lead to wide uptake of GastroClear, its blood-based quantitative PCR test for the detection of gastric or stomach cancer.
NEW YORK – Singaporean molecular diagnostics company MirXes believes the results of a new clinical validation study will lead to wide uptake of GastroClear, its blood-based quantitative PCR test for the detection of gastric or stomach cancer.
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.